How does giving a little vs. a lot of information about screening for ovarian cancer based on genetic risk assessment influence thoughts and feelings about taking part in ovarian cancer genetic testing and screening?

The impact of brief vs. extended information about personalized, risk-stratified ovarian cancer screening based on genetic risk assessment on intentions to participate in risk-stratified ovarian cancer screening: study protocol for a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48627877

Enrollment

600

Registered

2015-04-28

Start date

2015-05-01

Completion date

Unknown

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer screening Cancer

Interventions

We will create two versions of a website outlining information about OC risk, genetic testing and the risk-stratification programme (PROMISE) for the purpose of this study. With the exception of conte

resembling a ‘usual care’ arm of the trial. Following baseline measurements, participants randomized to the ‘extended’ version of the website will will also be invited to browse the website at their

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women 2. Aged 18-74 3. Able to give informed consent 4. No personal history of ovarian cancer

Exclusion criteria

Exclusion criteria: 1. Women not able to give informed consent 2. Personal history of ovarian cancer

Design outcomes

Primary

Measure	Time frame
Intention to participate in personalized-risk stratified OC screening, measured 1-2 weeks after the intervention	—

Secondary

Measure	Time frame
1. Changes in knowledge about ovarian cancer and genetic literacy 2. Decision satisfaction Measured 1-2 weeks after the intervention.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026